aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2021-17-4-93-100ateroskleroz-549Research ArticleОБЗОРЫREVIEWSСфинголипиды при ишемическом инсультеSphingolipids in ischemic strokehttps://orcid.org/0000-0002-9742-359XРогожинаА. А.RogozhinaA. A.

Анастасия Александровна Рогожина, аспирант кафедры терапии, кардиологии и функциональной диагностики ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ; врач-терапевт ГБУЗ «Городская клиническая больница № 51 ДЗ г. Москвы

121359, г. Москва ул. Маршала Тимошенко, 19, с. 1А121309, г. Москва, ул. Алябьева, 7/33

Anastasia A. Rogozhina, postgraduate student of the department of therapy, cardiology and functional diagnostics of the Central State Medical Academy of Department of Presidential Affairs; doctor of general medicine in the City Clinical Hospital № 51

121359, Moscow, Marchal Timoshenko, 19, s. 1A121309, Moscow, Alyab’eva str., 7/33

rogozhina007@list.ruФГБОУ ДПО «Центральная государственная медицинская академия» УД Президента РФ; ГБУЗ «Городская клиническая больница № 51 ДЗ г. Москвы»РоссияCentral State Medical Academy of Department of Presidential Affairs; City Clinical HospitalRussian Federation20211301202217493100Copyright © Рогожина А.А., 20222022Рогожина А.А.Rogozhina A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/549

Определение новых биомаркеров, участвующих в патогенезе ишемического инсульта, является чрезвычайно важной задачей с точки зрения определения возможных механизмов профилактики возникновения острого события, лучшей диагностики и воздействия на этапы патогенеза для разрешения воспаления. Сфинголипиды относят к новым биомаркерам атеросклероза, которые участвуют в воспалении, апоптозе и ишемии. Широкое внедрение масс-спектрометрии позволило изучать их более детально. Целью настоящего обзора является обобщение имеющихся данных о роли сфинголипидов при ишемическом инсульте.

Determination of new biomarkers involved in the pathogenesis of ischemic stroke is an extremely important task from the point of view of identifying possible mechanisms for preventing the occurrence of an acute event, better diagnosis, and influencing the stages of pathogenesis to reduce the inflammatory focus. Sphingolipids belong to new biomarkers of atherosclerosis, which are involved in inflammation, apoptosis, and ischemia. The widespread introduction of mass spectrometry has made it possible to study sphingolipids in more detail. This review aims to summarize the available data on the role of sphingolipids in ischemic stroke.

ишемический инсультсфинголипидымасс-спектрометрияцерамидысфингозин-1-фосфатischemic strokesphingolipidsmass-spectrometryceramidessphingosine-1-phosphateReferencesPettus B.J., Chalfant C.E., Hannun Y.A. Ceramide in apoptosis: an overview and current perspectives. Biochim. Biophys. Acta, 2002; 1585 (2-3): 114–125. doi:10.1016/s1388-1981(02)00331-1Pettus B.J., Chalfant C.E., Hannun Y.A. Ceramide in apoptosis: an overview and current perspectives. Biochim. Biophys. Acta, 2002; 1585 (2-3): 114–125. doi:10.1016/s1388-1981(02)00331-1Mohamud Y.A., Hagemann N., Hermann D.M. The acid sphingomyelinase/ceramide system as target for ischemic stroke therapies. Neurosignals, 2019; 27 (S1): 32–43. doi:10.33594/000000184Mohamud Y.A., Hagemann N., Hermann D.M. The acid sphingomyelinase/ceramide system as target for ischemic stroke therapies. Neurosignals, 2019; 27 (S1): 32–43. doi:10.33594/000000184Алесенко А.В., Затейщиков Д.А., Лебедев А.Т., Курочкин И.Н. Участие сфинголипидов в патогенезе атеросклероза. Кардиология, 2019; 59 (8): 77–87.Алесенко А.В., Затейщиков Д.А., Лебедев А.Т., Курочкин И.Н. Участие сфинголипидов в патогенезе атеросклероза. Кардиология, 2019; 59 (8): 77–87.Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature reviews. Mol. Cell Biol., 2008; 9 (2): 139–150. doi:10.1038/nrm2329Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature reviews. Mol. Cell Biol., 2008; 9 (2): 139–150. doi:10.1038/nrm2329Manicke N.E., Nefliu M., Wu C., Woods J.W., Reiser V., Hendrickson R.C., Cooks R.G. Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry. Anal. Chem., 2009; 81 (21): 8702–8707. doi:10.1021/ac901739sManicke N.E., Nefliu M., Wu C., Woods J.W., Reiser V., Hendrickson R.C., Cooks R.G. Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry. Anal. Chem., 2009; 81 (21): 8702–8707. doi:10.1021/ac901739sBrunkhorst R., Friedlaender F., Ferreirós N., Schwalm S., Koch A., Grammatikos G., Toennes S., Foerch C., Pfeilschifter J., Pfeilschifter W. Alterations of the ceramide metabolism in the peri-infarct cortex are independent of the sphingomyelinase pathway and not influenced by the acid sphingomyelinase inhibitor fluoxetine. Neural Plasticity, 2015; 2015: 503079. doi:10.1155/2015/503079Brunkhorst R., Friedlaender F., Ferreirós N., Schwalm S., Koch A., Grammatikos G., Toennes S., Foerch C., Pfeilschifter J., Pfeilschifter W. Alterations of the ceramide metabolism in the peri-infarct cortex are independent of the sphingomyelinase pathway and not influenced by the acid sphingomyelinase inhibitor fluoxetine. Neural Plasticity, 2015; 2015: 503079. doi:10.1155/2015/503079Abe T., Niizuma K., Kanoke A., Saigusa D., Saito R., Uruno A., Fujimura M., Yamamoto M., Tominaga T. Metabolomic analysis of mouse brain after a transient middle cerebral artery occlusion by mass spectrometry imaging. Neurol. Medico-Chirur., 2018; 58 (9): 384–392. doi:10.2176/nmc.oa.2018-0054Abe T., Niizuma K., Kanoke A., Saigusa D., Saito R., Uruno A., Fujimura M., Yamamoto M., Tominaga T. Metabolomic analysis of mouse brain after a transient middle cerebral artery occlusion by mass spectrometry imaging. Neurol. Medico-Chirur., 2018; 58 (9): 384–392. doi:10.2176/nmc.oa.2018-0054Henderson F., Hart P.J., Pradillo J.M., Kassiou M., Christie L., Williams K.J., Boutin H., McMahon A. Multi-modal imaging of long-term recovery poststroke by positron emission tomography and matrixassisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom., 2018; 32 (9): 721–729. doi:10.1002/rcm.8090Henderson F., Hart P.J., Pradillo J.M., Kassiou M., Christie L., Williams K.J., Boutin H., McMahon A. Multi-modal imaging of long-term recovery poststroke by positron emission tomography and matrixassisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom., 2018; 32 (9): 721–729. doi:10.1002/rcm.8090Nielsen M.M., Lambertsen K.L., Clausen B.H., Meyer M., Bhandari D.R., Larsen S.T., Poulsen S.S., Spengler B., Janfelt C., Hansen H.S. Mass spectrometry imaging of biomarker lipids for phagocytosis and signalling during focal cerebral ischaemia. Sci. Rep., 2016; 6: 39571. doi:10.1038/srep39571Nielsen M.M., Lambertsen K.L., Clausen B.H., Meyer M., Bhandari D.R., Larsen S.T., Poulsen S.S., Spengler B., Janfelt C., Hansen H.S. Mass spectrometry imaging of biomarker lipids for phagocytosis and signalling during focal cerebral ischaemia. Sci. Rep., 2016; 6: 39571. doi:10.1038/srep39571Le Stunff H., Milstien S., Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J. Cell. Biochem., 2004; 92 (5): 882–899. doi:10.1002/jcb.20097Le Stunff H., Milstien S., Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J. Cell. Biochem., 2004; 92 (5): 882–899. doi:10.1002/jcb.20097Urtz N., Gaertner F., von Bruehl M.L., Chandraratne S., Rahimi F., Zhang L., Orban M., Barocke V., Beil J., Schubert I., Lorenz M., Legate K.R., Huwiler A., Pfeilschifter J.M., Beerli C., Ledieu D., Persohn E., Billich A., Baumruker T., Mederos y Schnitzler M., Massberg S. Sphingosine 1-phosphate produced by sphingosine kinase 2 intrinsically controls platelet aggregation in vitro and in vivo. Circ. Res., 2015; 117 (4): 376–387. doi:10.1161/circresaha.115.306901Urtz N., Gaertner F., von Bruehl M.L., Chandraratne S., Rahimi F., Zhang L., Orban M., Barocke V., Beil J., Schubert I., Lorenz M., Legate K.R., Huwiler A., Pfeilschifter J.M., Beerli C., Ledieu D., Persohn E., Billich A., Baumruker T., Mederos y Schnitzler M., Massberg S. Sphingosine 1-phosphate produced by sphingosine kinase 2 intrinsically controls platelet aggregation in vitro and in vivo. Circ. Res., 2015; 117 (4): 376–387. doi:10.1161/circresaha.115.306901Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim. Biophys. Acta, 2002; 1582 (1-3): 132–137. doi:10.1016/s1388-1981(02)00147-6Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim. Biophys. Acta, 2002; 1582 (1-3): 132–137. doi:10.1016/s1388-1981(02)00147-6Kurano M., Yatomi Y. Sphingosine 1-phosphate and atherosclerosis. J. Atheroscler. Thromb., 2018; 25 (1): 16–26. doi:10.5551/jat.RV17010Kurano M., Yatomi Y. Sphingosine 1-phosphate and atherosclerosis. J. Atheroscler. Thromb., 2018; 25 (1): 16–26. doi:10.5551/jat.RV17010Kimura T., Sato K., Malchinkhuu E., Tomura H., Tamama K., Kuwabara A., Murakami M., Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol., 2003; 23 (7): 1283–1288. doi:10.1161/01.atv.0000079011.67194.5aKimura T., Sato K., Malchinkhuu E., Tomura H., Tamama K., Kuwabara A., Murakami M., Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol., 2003; 23 (7): 1283–1288. doi:10.1161/01.atv.0000079011.67194.5aNofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., Tietge U.J., Gödecke A., Ishii I., Kleuser B., Schäfers M., Fobker M., Zidek W., Assmann G., Chun J., Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest., 2004; 113 (4): 569–581. doi:10.1172/jci18004Nofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., Tietge U.J., Gödecke A., Ishii I., Kleuser B., Schäfers M., Fobker M., Zidek W., Assmann G., Chun J., Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest., 2004; 113 (4): 569–581. doi:10.1172/jci18004Kimura T., Tomura H., Mogi C., Kuwabara A., Damirin A., Ishizuka T., Sekiguchi A., Ishiwara M., Im D.S., Sato K., Murakami M., Okajima F. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoproteininduced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem., 2006; 281 (49): 37457–37467. doi:10.1074/jbc.M605823200Kimura T., Tomura H., Mogi C., Kuwabara A., Damirin A., Ishizuka T., Sekiguchi A., Ishiwara M., Im D.S., Sato K., Murakami M., Okajima F. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoproteininduced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem., 2006; 281 (49): 37457–37467. doi:10.1074/jbc.M605823200Ruiz M., Frej C., Holmer A., Guo L.J., Tran S., Dahlback B. High-density lipoprotein-associated apolipoprotein m limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1. Arterioscler. Thromb. Vasc. Biol, 2017; 37 (1): 118–129. doi:10.1161/ATVBAHA.116.308435Ruiz M., Frej C., Holmer A., Guo L.J., Tran S., Dahlback B. High-density lipoprotein-associated apolipoprotein m limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1. Arterioscler. Thromb. Vasc. Biol, 2017; 37 (1): 118–129. doi:10.1161/ATVBAHA.116.308435Tamama K., Tomura H., Sato K., Malchinkhuu E., Damirin A., Kimura T., Kuwabara A., Murakami M., Okajima F. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis, 2005; 178 (1): 19–23. doi:10.1016/j.atherosclerosis.2004.07.032Tamama K., Tomura H., Sato K., Malchinkhuu E., Damirin A., Kimura T., Kuwabara A., Murakami M., Okajima F. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis, 2005; 178 (1): 19–23. doi:10.1016/j.atherosclerosis.2004.07.032Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 2004; 427 (6972): 355–360. doi:10.1038/nature02284Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 2004; 427 (6972): 355–360. doi:10.1038/nature02284Drouillard A., Neyra A., Mathieu A.L., Marçais A., Wencker M., Marvel J., Belot A., Walzer T. Human naive and memory T cells display opposite migratory responses to sphingosine-1 phosphate. J. Immunol, 2018; 200 (2): 551–557. doi:10.4049/jimmunol.1701278Drouillard A., Neyra A., Mathieu A.L., Marçais A., Wencker M., Marvel J., Belot A., Walzer T. Human naive and memory T cells display opposite migratory responses to sphingosine-1 phosphate. J. Immunol, 2018; 200 (2): 551–557. doi:10.4049/jimmunol.1701278Lucaciu A., Kuhn H., Trautmann S., Ferreirós N., Steinmetz H., Pfeilschifter J., Brunkhorst R., Pfeilschifter W., Subburayalu J., Vutukuri R. A Sphingosine 1-phosphate gradient is linked to the cerebral recruitment of T helper and regulatory T helper cells during acute ischemic stroke. Int. J. Mol. Sci., 2020; 21 (17). doi:10.3390/ijms21176242Lucaciu A., Kuhn H., Trautmann S., Ferreirós N., Steinmetz H., Pfeilschifter J., Brunkhorst R., Pfeilschifter W., Subburayalu J., Vutukuri R. A Sphingosine 1-phosphate gradient is linked to the cerebral recruitment of T helper and regulatory T helper cells during acute ischemic stroke. Int. J. Mol. Sci., 2020; 21 (17). doi:10.3390/ijms21176242Cao R., Li J., Kharel Y., Zhang C., Morris E., Santos W.L., Lynch K.R., Zuo Z., Hu S. Photoacoustic microscopy reveals the hemodynamic basis of sphingosine 1-phosphate-induced neuroprotection against ischemic stroke. Theranostics, 2018; 8 (22): 6111–6120. doi:10.7150/thno.29435Cao R., Li J., Kharel Y., Zhang C., Morris E., Santos W.L., Lynch K.R., Zuo Z., Hu S. Photoacoustic microscopy reveals the hemodynamic basis of sphingosine 1-phosphate-induced neuroprotection against ischemic stroke. Theranostics, 2018; 8 (22): 6111–6120. doi:10.7150/thno.29435Bojic L.A., McLaren D.G., Shah V., Previs S.F., Johns D.G., Castro-Perez J.M. Lipidome of atherosclerotic plaques from hypercholesterolemic rabbits. Int. J. Mol. Sci., 2014; 15 (12): 23283–23293. doi:10.3390/ijms151223283Bojic L.A., McLaren D.G., Shah V., Previs S.F., Johns D.G., Castro-Perez J.M. Lipidome of atherosclerotic plaques from hypercholesterolemic rabbits. Int. J. Mol. Sci., 2014; 15 (12): 23283–23293. doi:10.3390/ijms151223283Vorkas P.A., Shalhoub J., Lewis M.R., Spagou K., Want E.J., Nicholson J.K., Davies A.H., Holmes E. Metabolic phenotypes of carotid atherosclerotic plaques relate to stroke risk: an exploratory study. Eur. J. Vasc. Endovasc. Surg., 2016; 52 (1): 5–10. doi:10.1016/j.ejvs.2016.01.022Vorkas P.A., Shalhoub J., Lewis M.R., Spagou K., Want E.J., Nicholson J.K., Davies A.H., Holmes E. Metabolic phenotypes of carotid atherosclerotic plaques relate to stroke risk: an exploratory study. Eur. J. Vasc. Endovasc. Surg., 2016; 52 (1): 5–10. doi:10.1016/j.ejvs.2016.01.022Edsfeldt A., Dunér P., Ståhlman M., Mollet I.G., Asciutto G., Grufman H., Nitulescu M., Persson A.F., Fisher R.M., Melander O., Orho-Melander M., Borén J., Nilsson J., Gonçalves I. Sphingolipids contribute to human atherosclerotic plaque inflammation. Arterioscler. Thromb. Vasc. Biol., 2016; 36 (6): 1132– 1140. doi:10.1161/atvbaha.116.305675Edsfeldt A., Dunér P., Ståhlman M., Mollet I.G., Asciutto G., Grufman H., Nitulescu M., Persson A.F., Fisher R.M., Melander O., Orho-Melander M., Borén J., Nilsson J., Gonçalves I. Sphingolipids contribute to human atherosclerotic plaque inflammation. Arterioscler. Thromb. Vasc. Biol., 2016; 36 (6): 1132– 1140. doi:10.1161/atvbaha.116.305675Testai F.D., Hillmann M., Amin-Hanjani S., Gorshkova I., Berdyshev E., Gorelick P.B., Dawson G. Changes in the cerebrospinal fluid ceramide profile after subarachnoid hemorrhage. Stroke, 2012; 43 (8): 2066–2070. doi:10.1161/strokeaha.112.650390Testai F.D., Hillmann M., Amin-Hanjani S., Gorshkova I., Berdyshev E., Gorelick P.B., Dawson G. Changes in the cerebrospinal fluid ceramide profile after subarachnoid hemorrhage. Stroke, 2012; 43 (8): 2066–2070. doi:10.1161/strokeaha.112.650390Fiedorowicz A., Kozak-Sykała A., Bobak Ł., Kałas W., Strządała L. Ceramides and sphingosine-1-phosphate as potential markers in diagnosis of ischaemic stroke. Neurologia i neurochirurgia polska, 2019; 53 (6): 484– 491. doi:10.5603/PJNNS.a2019.0063Fiedorowicz A., Kozak-Sykała A., Bobak Ł., Kałas W., Strządała L. Ceramides and sphingosine-1-phosphate as potential markers in diagnosis of ischaemic stroke. Neurologia i neurochirurgia polska, 2019; 53 (6): 484– 491. doi:10.5603/PJNNS.a2019.0063Gui Y.K., Li Q., Liu L., Zeng P., Ren R.F., Guo Z.F., Wang G.H., Song J.G., Zhang P. Plasma levels of ceramides relate to ischemic stroke risk and clinical severity. Brain Res. Bull., 2020; 158: 122–127. doi:10.1016/j.brainresbull.2020.03.009Gui Y.K., Li Q., Liu L., Zeng P., Ren R.F., Guo Z.F., Wang G.H., Song J.G., Zhang P. Plasma levels of ceramides relate to ischemic stroke risk and clinical severity. Brain Res. Bull., 2020; 158: 122–127. doi:10.1016/j.brainresbull.2020.03.009Chao H.C., Lee T.H., Chiang C.S., Yang S.Y., Kuo C.H., Tang S.C. Sphingolipidomics investigation of the temporal dynamics after ischemic brain injury. J. Proteome Res., 2019; 18 (9): 3470–3478. doi:10.1021/acs.jproteome.9b00370Chao H.C., Lee T.H., Chiang C.S., Yang S.Y., Kuo C.H., Tang S.C. Sphingolipidomics investigation of the temporal dynamics after ischemic brain injury. J. Proteome Res., 2019; 18 (9): 3470–3478. doi:10.1021/acs.jproteome.9b00370Guo X., Li Z., Zhou Y., Yu S., Yang H., Zheng L., Liu Y., Sun Y. Metabolic profile for prediction of ischemic stroke in chinese hypertensive population. J. Stroke Cerebrovasc. Dis., 2019; 28 (4): 1062–1069. doi:10.1016/j.jstrokecerebrovasdis.2018.12.035Guo X., Li Z., Zhou Y., Yu S., Yang H., Zheng L., Liu Y., Sun Y. Metabolic profile for prediction of ischemic stroke in chinese hypertensive population. J. Stroke Cerebrovasc. Dis., 2019; 28 (4): 1062–1069. doi:10.1016/j.jstrokecerebrovasdis.2018.12.035Lind L., Salihovic S., Ganna A., Sundstrom J., Broeckling C.D., Magnusson P.K., Pedersen N.L., Siegbahn A., Prenni J., Fall T., Ingelsson E., Arnlov J. A Multi-cohort metabolomics analysis discloses sphingomyelin (32:1) levels to be inversely related to incident ischemic stroke. J. Stroke Cerebrovasc., Dis., 2020; 29 (2): 104476. doi:10.1016/j.jstrokecerebrovasdis.2019.104476Lind L., Salihovic S., Ganna A., Sundstrom J., Broeckling C.D., Magnusson P.K., Pedersen N.L., Siegbahn A., Prenni J., Fall T., Ingelsson E., Arnlov J. A Multi-cohort metabolomics analysis discloses sphingomyelin (32:1) levels to be inversely related to incident ischemic stroke. J. Stroke Cerebrovasc., Dis., 2020; 29 (2): 104476. doi:10.1016/j.jstrokecerebrovasdis.2019.104476

The authors declare that there are no conflicts of interest present.